An oncologist from Atrium Health outlines how saving time administering immunotherapy could have far-reaching benefits.

Celltrion today announced the U.S. launch of STEQEYMA��(ustekinumab-stba), a biosimilar to STELARA� (ustekinumab), following approval by the U.S. Food and Drug Administration (FDA) in December 2024.

In some cases, a painless injection is all that is now needed ... many as five biosimilars competing with Genentech’s biologic Herceptin, which treats early-stage breast cancer.

Herceptin, and Rituxan/MabThera lose their patent protection and face competition from cheaper near-copy biosimilars. It already has a haemophilia A injection on the market, Hemlibra, which acts ...

This drug works by combining the antibody trastuzumab with a drug called emtansine. Trastuzumab works by binding to HER2 proteins that are found on the cells of HER2-positive breast cancer.

STEQEYMA®, one of the first-wave biosimilars to STELARA®, is now available in the U.S. Approved for the same indications as ...

OMLYCLO® (omalizumab-igec) is the first and only omalizumab biosimilar approved by the FDA Regulatory approval for ...

It is available in both subcutaneous injection and intravenous infusion.[1] "Chronic inflammatory diseases such as plaque psoriasis and psoriatic arthritis place significant burden on patients ...

The slugger will head back to New York on Monday for yet another round of PRP injections on his ailing elbows, a team spokesman said Friday. Stanton had been away since Feb. 24 to deal with a ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

When giving gluteal injections, it is safest to use the upper outer quadrant. The choice of site for injection must be based on good clinical judgment, using the best evidence available and ...